This dopaminergic hypothesis of schizophrenia has been also supported by the correlation between efficacy of antipsychotic drugs in treating schizophrenia and their potency to antagonize the binding of DA to DRD2 [171,172,173], as well as by the ability of dopaminergic agents, such as psychostimulant amphetamine, to induce excessive release of striatal DA and stimulate schizophrenia-like psychosis [174,175,176]. The gene discussed is DRD2; the disease is schizophrenia.